Acumen Pharmaceuticals Inc
acumenpharm.comAcumen Pharmaceuticals (NASDAQ: ABOS) is a clinical-stage biopharmaceutical company developing a single product candidate, sabirnetug, targeting amyloid-beta oligomers (AßOs) for the treatment of Alzheimer's disease. The company generates no revenue from product sales and has not commercialized any products as of its FY2025 10-K filed March 26, 2026. Acumen has funded operations primarily through equity sales, convertible preferred stock, notes, and a term loan facility with K2 HealthVentures LLC totaling up to $50.0 million, of which $30.0 million had been drawn as of the filing. Incorporated in 1996, the company acquired exclusive rights to sabirnetug from Merck & Co. in 2011 and did not recommence meaningful operations until 2018. Daniel O'Connell serves as Chief Executive Officer. Sabirnetug has completed a Phase 1 trial (INTERCEPT-AD), which demonstrated near-maximal target engagement of AßOs at doses of 25 mg/kg Q2W and 60 mg/kg Q4W. All research and development activities rely on third-party CROs and CMOs, with no separately tracked program expenses given the single-asset pipeline.
Products & Services
Sabirnetug (ACU3B3): a monoclonal antibody targeting amyloid-beta oligomers (AßOs) for Alzheimer's disease, in clinical development as of FY2025. No approved products.
Revenue Model
No product revenue as of FY2025. Operations funded through equity issuances, debt (term loan facility up to $50.0 million with K2 HealthVentures LLC, $30.0 million drawn), and historical grant and collaboration payments from Merck & Co.
Customers & Markets
No commercial customers. End market is Alzheimer's disease treatment. Target patient population is individuals with Alzheimer's disease.
Geographic Exposure
Incorporated and headquartered in the United States. No geographic revenue breakdown disclosed given no product sales.
Financial Snapshot
Loading...
